European Study Shows Promise of Intraoperative Radiation Therapy in Treatment of Early-Stage Breast Cancer.

SUNNYVALE, Calif. -- The benefit of Intraop Medical Corporation's (OTCBB: IOPM) Mobetron received a major boost due to a recent study involving 1,018 patients that documented the advantages of Intraoperative Radiation Therapy (IORT) in improving the results of early stage breast cancer treatment.

This extensive study hosted by six European cancer treatment centers and conducted by the International Society of IORT-Europe, followed the 1,018 women post IORT-treatment for a median time period of 39 months. While more than half of the patients had one or more adverse factors, there were only 3 in-breast recurrences, and only 38 patients developed further metastatic disease.

Dr. Donald A. Goer, President and CEO of Intraop, which manufactures and sells a unique, mobile electron-beam system called the "Mobetron," designed to apply radiation to the tumor while the patient is undergoing cancer surgery (e.g.: IORT), commented on the study results, saying, "If we assume that these patients had been treated with conventional breast-conserving therapy without IORT, based on published literature, the results would have been quite different and statistics show that one would have expected about 25 breast recurrences, and more than 65 of the patients would have developed metastatic disease. This was not the case as documented, due to the use of IORT." Dr. Goer elaborated, "We look to this study as solid support for our marketing initiative. Our Mobetron offers all the advantages of IORT, with the significant advantage of being mobile and compact enough to fit right into the surgical environment."

The 5-year disease-specific survival rate of study subjects was 99.1%, and the 5-year overall survival rate was 96.5%. At the study's conclusion there were 977 patients still alive, without disease and with a preserved breast.

This was the first pooled analysis by the ISIORT-Europe on the clinical outcomes of patients treated with IORT. Due to these encouraging results, the ISIORT-Europe is planning a prospective randomized trial on anticipated IORT breast boost. The ISIORT-Europe also plans to present the results of IORT on other tumor sites in the months ahead.

Recently, the British publication, Lancet, also highlighted improved survival results of 42,000 early-stage breast cancer patients, that were treated with techniques that increased local control in breast cancer.

"The Intraop Medical Corporation team is encouraged by these and other studies, along with the positive feedback we continue to receive from physicians and health care professionals. Our conviction is stronger than ever that IORT is a major advance that can and will be more extensively used for breast cancer treatment and that the Mobetron offers patients, doctors and hospitals the best option for mobile, convenient IORT," says Dr. Goer. "This is positive news for patients, for hospitals, and certainly for our company."

Mobetron, the first mobile device for delivering IORT in the operating room without the necessity of adding extensive radiation shielding is FDA approved for sale in the United States and has received the equivalent foreign approvals: CE Mark in Europe, JIS in Japan and SDA in China. Mobetron's are currently in use at: Mayo Clinic, University of California at San Francisco, Methodist Hospitals of Indianapolis, University of Louisville, University of North Carolina-Chapel Hill, University Hospital of Cleveland, Ohio State University, and in several locations in Italy, Japan, The Netherlands, Poland and Spain.

The results of this study were presented in Salzburg at the Austrian Radiation Oncology Meeting by Dr. Felix Sedlymayer, Professor and Chairman of the Dept. of Radiation Oncology at the University of Salzburg, Austria.

About Intraop Medical Corporation

Intraop Medical Corporation improves the quality of life for cancer patients through the development, manufacturing and sales of its proprietary Mobetron system. The Mobetron is a mobile electron-beam system designed for Intraoperative radiation therapy (IORT) treatment of cancer, coronary/vascular restenosis and other medical applications. IORT is the direct application of radiation to a tumor while a patient is undergoing cancer surgery. Intraop Medical Corporation has revolutionized this procedure by developing the first mobile device for delivering IORT in the operating room without the necessity of adding extensive radiation shielding. The Mobetron is easily transportable between operating rooms and/or hospitals, further increasing system usage. The system is FDA-approved for sale in the United States and has received the equivalent foreign approvals: CE Mark in Europe, JIS in Japan and SDA in China. Intraop Medical Corporation is based in Sunnyvale, California. For more information on Intraop Medical Corporation please visit www.Intraopmedical.com.

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.